Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT01701986

Public ClinicalTrials.gov record NCT01701986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas

Study identification

NCT ID
NCT01701986
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
M.D. Anderson Cancer Center
Other
Enrollment
64 participants

Conditions and interventions

Interventions

  • Allogeneic Bone Marrow Transplantation Procedure
  • Allogeneic Hematopoietic Stem Cell Transplantation Procedure
  • Anti-Thymocyte Globulin Biological
  • Busulfan Drug
  • Clofarabine Drug
  • Gemcitabine Hydrochloride Drug
  • Mycophenolate Mofetil Drug
  • Peripheral Blood Stem Cell Transplantation Procedure
  • Pharmacological Study Other
  • Rituximab Biological
  • Tacrolimus Drug

Procedure · Biological · Drug + 1 more

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 24, 2012
Primary completion
Jun 4, 2024
Completion
Jun 4, 2024
Last update posted
Feb 27, 2025

2012 – 2024

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01701986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 27, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01701986 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →